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Dihydroceramide desaturase is the last enzyme in the biosynthesis of ceramide de novo. The cyclopropene-containing
sphingolipid GT11 is a competitive inhibitor of dihydroceramide desaturase. The biological effects of chemical
modiﬁcation of the GT11 amide linkage are reported in this article. Either N-methyl substitution or replacement of
the amide a-carbonyl methylene by oxygen result in inactive compounds. In contrast, both urea (3) and thiourea (4)
analogs of GT11, as well as three a-ketoamides (5–7), did inhibit the desaturation of N-octanoylsphinganine to
N-octanoylsphingosine, although with signiﬁcantly lower potency than GT11. Furthermore, the a-ketoamides 5–7
inhibit the acidic ceramidase with similar potencies (IC50 52–83 lM). Inhibition of the neutral/alkaline ceramidase
by these compounds requires around 20-fold higher concentrations. Structure–activity relationships and the
biological interest of these compounds are discussed.
Introduction
Besides its essential roles in cell biology, ceramide is the
central molecule in the biosynthesis of sphingolipids and
glycosphingolipids, which are also crucial in regulating vari-
ous cell functions.1 De novo biosynthesis of ceramide occurs
from L-serine,2 which is condensed with palmitoyl-CoA to
give 3-ketosphinganine. Further reduction and subsequent N-
acylation afford dihydroceramide, which is ﬁnally converted
into ceramide by dihydroceramide desaturase.3 Two differ-
ent dihydroceramide desaturases have been so far reported,
namely DES1,4 which exhibits delta-4 desaturase activity,
and DES2,5 which has bifunctional delta-4 desaturase and
hydroxylase activities. The latter is especially abundant in skin,
intestines, and kidney, sites reportedly possessing high levels
of phytosphingolipids.5 Catabolism of ceramide occurs by the
action of ceramidases, which hydrolyze the amide bond to
yield the sphingosine moiety and fatty acids. According to
their pH optima for activity, ceramidases fall into three groups,
acidic, neutral and alkaline. The acid ceramidase is localized in
the lysosomes and its defect causes Farber’s disease.6 Neutral
ceramidases have been reported in several species7 and they are
localized in the endoplasmic reticulum and the mitochondria.
Finally, alkaline ceramidases have also been found in guinea
pig,8 human skin,9 bacteria10 and yeast.11
The cyclopropene-containing sphingolipid GT11 is a com-
petitive inhibitor of dihydroceramide desaturase with a K i of
6 lM.12 Structure–activity correlations showed that the presence
of a cyclopropene ring in place of the ceramide double bond,
the natural 2S,3R stereochemistry, and a free hydroxyl group
at C1 are required for inhibition.12 Although it was also
shown that a similar N-acyl chain length in both substrate
and cyclopropene inhibitor were essential for inhibitory activity
in vitro,12 modiﬁcations of the GT11 amide linkage other
than the N-acyl chain length were not performed. In light
of several articles reporting on substrate based inhibitors of
mitochondrial ceramidase13 and fatty acid amide hydrolases,14–16
suchmodiﬁcationsmight affordGT11analogswith either higher
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metabolic stability toward ceramidases or additional activity as
ceramidase inhibitors. Bothmetabolically stable and ceramidase
inhibitor analogs of GT11 would be of interest, since GT11 is
partly degraded by ceramidases in cultured cells.17 In this article
we describe the synthesis of several analogs of GT11 (Fig. 1),
and their in vitro activity on dihydroceramide desaturase and
both the neutral/alkaline and the acidic ceramidase.
Fig. 1 Compounds used in this study.
Results
Synthesis of GT11 analogues
The N-methylamide derivative 1 was obtained from GT1112
through a protection–deprotection sequence (Scheme 1). Thus,
GT11 was transformed into the dioxolane 8 under standard
conditions. Treatment of 8 with NaH and further reaction with
MeI afforded 9, which gave rise to the expected analog 1 upon
mild acid hydrolysis.
The carbamate 2 and urea 3 were obtained in moderate yields
by reaction of the aminodiol 1018 with octyl chloroformate
and octyl isocyanate, respectively (Scheme 2). In the synthesis
of 2, reaction until complete consumption of the starting
material afforded mixtures of the expected carbamate along
with two other carbamates having each of the two hydroxyl
groups esteriﬁed with octylcarbonic acid. Careful monitoring
of the reaction course by thin layer chromatography and its
immediate quenching as soon as carbonates were noticeable,DO
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Scheme 1 Synthesis of 1. a, 2,2-dimethoxypropane, pyridinium
p-toluenesulfonate, CH2Cl2; b, sodium hydride, dimethyl sulfoxide, then
methyl iodide in tetrahydrofuran; c, p-toluenesulfonic acid in methanol
(40% overall yield from 8).
Scheme 2 Synthesis of 2–7 and GT11-C12NBD. a, CH3(CH2)7CO2Cl
in methylene chloride–triethylamine; b, CH3(CH2)7NCO in diethyl
ether–acetonitrile; c, CH3(CH2)7NCS in diethyl ether–acetonitrile; d,
treatment with the appropriate acid in the presence of EDC–HOBT
in either methylene chloride or diethyl ether–acetonitrile. Acids
are NBD(CH2)11COOH (GT11-C12NBD); CH3CH2COCOOH (5);
CH3(CH2)5COCOOH (6) and C6H5COCOOH (7).
even with remaining starting material, allowed the preparation
of 2 in moderate yields (40%) in the absence of by-products.
The thiourea 4 was prepared by reaction of aminodiol 10 with
octyl isothiocyanate (Scheme 2). The a-ketoamides 5–7 were
synthesized from aminodiol 10 and the suitable a-ketoacid in the
presence of N-(3-dimethylaminopropyl)-N ′-ethylcarbodiimide
(EDC) and 1-hydroxybenzotriazole (HOBT) (Scheme 2). The
same procedure was followed to prepare the ﬂuorescent deriva-
tive of GT11 (GT11-C12NBD) from 10 and 12-(4-nitrobenzo-
2-oxa-1,3-diazolo)dodecanoic acid (Scheme 2).
Biological activities of the GT11 analogues
Inhibition of dihydroceramide desaturase. The effect of the
cyclopropeneceramides 1–7 on dihydroceramide desaturase was
investigated using rat liver microsomes and the previously
reported assay.12 Neither N-methylamide 1 nor carbamate 2
inhibited dihydroceramide desaturase. In contrast, both urea
3 and thiourea 4, as well as the three a-ketoamides 5–7
inhibited the desaturation of N-octanoylsphinganine to N-
octanoylsphingosine (Fig. 2), with inhibition percentages rang-
ing from 40 to 70% at equimolar concentrations of substrate and
inhibitor (50 lM). In the same experimental conditions, GT11
caused a 91% inhibition and was signiﬁcantly more potent that
the other 5 compounds.
Fig. 2 Effect of compounds GT11 and 1–7 on dihydroceramide
desaturase. The experiment was performed as detailed in ref. 21. The
amounts of N-octanoylsphingosine (NC8So) were calculated by gas
chromatography coupled to mass spectrometry relative to a known
amount of N-hexanoylsphingosine used as internal standard. The char-
acteristic ions at m/z 258 and 230, corresponding to the trimethylsilyl
derivatives of N-octanoylsphingosine and N-hexanoylsphingosine, re-
spectively, were used for quantiﬁcation. Data correspond to the mean ±
standard deviation of three replicates. Asterisks indicate statistical
signiﬁcance (unpaired two-tail t test, *, p ≤ 0.05; **, p≤ 0.005).
Ceramidase activity. The effect of the dihydroceramide de-
saturase inhibitors 3–7 on ceramidase activities was determined
by quantiﬁcation of the ﬂuorescent fatty acid released from
12-(4-nitro-benzo-2-oxa-1,3-diazolo)dodecylsphingosine (Cer-
C12NBD). While in previously reported assays19 both substrate
and acid were separated by HPLC, a modiﬁcation has been
introduced here consisting of the separation of both ﬂuorescent
species by ion exchange chromatography, using a commercially
available cation-exchange resin. Filtration of the reaction
mixture through the resin and washing with buffer-methanol at
pH ≥ 7.5 results in the elution of the unreacted substrate and
retention of the enzymatically released acid, which is then eluted
with a mixture of acetic acid–methanol. Aliquots of the several
fractions are ﬁnally transferred to 96-well plates, the ﬂuorescence
is determined and the actual amounts of both substrate and
product are calculated from standard curves. This assay was
validatedbyHPLC,which clearly showed that the neutral eluates
ﬁltered through the column contained only the Cer-C12NBD
substrate, whereas the acidic eluates contained exclusively the
ﬂuorescent acid (data not shown). In our conditions, hydro-
lysis of Cer-C12NBD by the neutral ceramidase preparation
occurred with an apparent Km of 106.7 lM and a Vmax of
17.3 pmolmin−1 mg−1 (Vmax/Km = 0.162). The acidic ceramidase
hydrolyzed Cer-C12NBD with a Km of 64.5 lM and a Vmax of
11.3 pmol min−1 mg−1 (Vmax/Km = 0.175).
To investigate the hydrolysis of GT11 by ceramidases, the
ﬂuorescent compound GT11-C12NBD, which was used as
substrate, was incubated with the suitable enzyme preparation
and the released ﬂuorescent fatty acid was quantiﬁed after
ion exchange chromatography of the incubation mixture. This
procedure evidenced that GT11-C12NBD was hydrolyzed by
the neutral ceramidase with a Km of 85.2 lM and a Vmax of
9.4 pmol/min/mg (Vmax/Km = 0.110) and by the acidic cerami-
dase with a Km of 69.2 lM and a Vmax of 6.9 pmol min−1 mg−1
(Vmax/Km = 0.100).
Inhibition of ceramidases. None of the dihydroceramide
desaturase inhibitors 3–7 inhibited the neutral ceramidase at
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Table 1 Effect of GT11 analogs on the neutral ceramidase
Control 3 4 5
Total acid released/nM 305 ± 6 80 ± 84 41 ± 22 120 ± 28
% Inhibition 74 86 61
a Enzyme activity was determined as indicated in the Experimental
section with 300 lg of protein using a substrate concentration of
25 lM and a 500 lM concentration of inhibitors. The amounts of
acid released after a 1 h incubation were determined after ion exchange
chromatography. Data correspond to the mean ± standard deviation
of four replicates. % Inhibition was calculated using the equation
100(acidcontrol − acidinhibitor/acidcontrol), where acidcontrol and acidinhibitor
correspond to the total amounts of acid released form mitochondria
incubated in the absence (untreated control) or the presence of inhibitors,
respectively.
equimolar concentrations (25 lM) with respect to the Cer-
C12NBD substrate, although they were presumably stable to-
wards deacylation.13 A 74% inhibition of the neutral ceramidase
was produced with 500 lM of the urea derivative 3 (substrate :
inhibitor molar ratio 1 : 20). In the same experimental condi-
tions, the thiourea 4 and ketoamide 5 produced 86% and 61%
inhibition, respectively (Table 1).
The GT11 analogs 3 and 4 were not inhibitors of the acid
ceramidase at equimolar concentrations with respect to the
substrate (40 lM). However, the a-ketoamides 5–7 did inhibit
this enzyme and the effect was concentration-dependent (Fig. 3).
The IC50 values obtained at a single substrate concentration
(40 lM) indicated that the three compounds 5–7 had similar
potencies (IC50 52–83 lM). Although kinetic studies were
conducted, the type of inhibition could not be ascertained,
probably because a non-puriﬁed homogenate was used as the
source of enzyme.
Fig. 3 Dose-response of a-ketoamides 5–7 on the acid ceramidase.
Enzyme activity was determined as indicated in the experimental section
using a substrate concentration of 40 lMand different concentrations of
inhibitors (10, 20, 40, 80 and 160 lM). Data correspond to the mean ±
standard deviation of a representative experiment with three replicates.
The IC50 values calculated on the basis of a regression analysis were: 5,
83 lM; 6, 61 lM; 7, 52 lM.
Discussion
Dihydroceramide desaturase is the last enzyme in the de novo
biosynthetic pathway of ceramide.3 Two different dihydro-
ceramide desaturases, DES14 and DES2,5 have so far been
reported. Although their amino acid sequences have high
identity, they differ in their enzymatic characteristics, since while
DES1 exhibits high dihydroceramide desaturase activity and
very low C-4 hydroxylase activity, DES2 is similarly active as
both a dihydroceramide desaturase and a C-4 hydroxylase. In
previous articles we reported that the cyclopropene-containing
sphingolipidGT11 is a competitive inhibitor of dihydroceramide
desaturase.12,18 In structure–activity correlation studies18 we
found that the natural 2S,3R stereochemistry, the amide func-
tion, the presence of a cyclopropene ring in place of the ceramide
double bond and a free hydroxyl group at C1 are required
for inhibition. Additional structure–activity correlations are
provided in this article, in which we report that N-methyl
substitution of GT11 results in the loss of inhibitory activity.
Although the steric hindrance of the methyl group can be
invoked to explain the lack of effect of 1, it is also possible that
the amido hydrogen atom, which is absent in theN-methylamide
1, is essential for inhibitory activity by virtue of its participation
in hydrogen bonding events required for inhibition, (i.e. enzyme–
inhibitor interactions or arrangement of the inhibitor into the
active conformation).
Interference with hydrogen bonding can also be a reason
for the ineffectiveness of carbamate 2 on dihydroceramide
desaturase, in contrast to the respective urea 3 and thiourea 4
analogs, which retain inhibitory activity. By means of its higher
hydrogen bond accepting character as compared to the urea
3 and thiourea 4 amino counterparts, the carbamate oxygen
of 2 may compete and thus interfere with hydrogen bonding
necessary for inhibition. Since the a-ketoamides 5–7 retained
dihydroceramide desaturase inhibitory activity, these overall
results indicate that some substitutions are allowed in the a
position of the amide carbonyl moiety of GT11, although they
result in less potent inhibitors than the lead compound.
Besides providing with additional structure–dihydroceramide
desaturase inhibitory activity correlations, the activity of some
GT11 analogs on ceramidases deserves attention. The urea
isostere of N-palmitoylsphingosine was reported as a competi-
tive inhibitor of the rat brain neutral ceramidase with a IC50 of
25 lM at 50 lM concentration of substrate (Cer-C12NBD).13
In contrast, the urea derivative of GT11 (2) had no effect
on the neutral ceramidase at equimolar concentrations with
respect to the substrate and high inhibitor : substrate molar
ratios were required for inhibition. This was also the case for
the thiourea isostere 4. Considering that N-acyl sphingosines
with acyl chain lengths below C10 are poor substrates of
the neutral ceramidase,20 it is possible that the short N-acyl
chain of the urea analog 3 (and thiourea 4) lowers the afﬁnity
of the enzyme for this compound, which would result in its
decreased potency as compared to the N-palmitoylsphingosine
urea analog. It has been shown that the neutral ceramidase
from rat brain hydrolyzes dihydroceramide at a 10-fold lower
rate than ceramide and that the cis analog of ceramide is not
hydrolyzed.20 Taking into account this substrate speciﬁcity, one
could argue that the presence of a cyclopropene ring in 3 (and
4) diminishes the enzyme afﬁnity for this compound, which is
signiﬁcantly less potent than the N-palmitoylsphingosine urea
analog. However, the ﬁnding that Cer-C12NBD and GT11-
C12NBD are hydrolyzed by the neutral ceramidase with similar
kinetic parameters seems to indicate that the cyclopropene
ring does not affect enzyme binding and therefore, the ﬁrst
explanation invoking the N-acyl chain length seems more
plausible.
Although several authors have reported that a-ketoamides are
competitive inhibitors of serine hydrolases, including fatty acid
amide hydrolases,14–16 the structural requirements of the neutral
ceramidase20 is also a likely explanation for the low effectiveness
of the a-ketoamides 5–7 on this enzyme. Therefore, despite the
occurrence of the a-ketoamide unit, sphingoid base acylation
with short a-ketoamide units lower the afﬁnity of the enzyme
for these compounds.
The GT11 analogs 3 and 4 did not inhibit the acidic
ceramidase. In contrast, a-ketoamides 5–7 inhibited this enzyme
in a concentration-dependent manner with similar potencies
(IC50 52–83 lM). As reported for a-ketoamide inhibitors of fatty
acid amide hydrolases,14 the electron-deﬁcient a-carbonyl group
does probably react with the active-site nucleophilic amino acid
to form an hemiacetal intermediate, which mimics the reaction
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transition state thus inhibiting the hydrolysis. The additional
features deﬁned in the different a-ketoamides may contribute
independently to enzyme binding afﬁnity. Although the activity
of the acid ceramidase in the presence of different amounts
of inhibitor while varying the substrate concentration was
investigated, no conclusive data as to the type of inhibition could
be obtained, probably because a non-puriﬁed lysosomal fraction
was used as the source of enzyme. Taking into account the results
reported for a-ketoamide inhibitors of amide hydrolases,16 a
competitive type of inhibitionwould be expected for compounds
5–7.
In a previous work17 we showed that in primary cultured
neurons, GT11 inhibited dihydroceramide desaturase in a con-
centration dependent manner (IC50 of 23 nM) with a potency by
three orders of magnitude higher than that found in vitro. How-
ever, although this inhibitory effect was speciﬁc at concentra-
tions up to 1 lM, higher concentrations (from 5 lMupwards) of
GT11 not only abolished desaturation of dihydroceramide, but
also impaired de novo sphingolipid biosynthesis by an indirect
suppression of serine palmitoyltransferase activity. Metabolic
studies with radioactively labeled GT11 analogs indicated that
the inhibitor is subjected to catabolism by ceramidases to yield
the cyclopropene-bearing long chain base. In this study we show
that in vitro N-deacylation of GT11 is produced by both the
acidic and the neutral ceramidase. Although the free cyclo-
propene base does not inhibit dihydroceramide desaturase,18 it
cannot be completely disregarded that deacylated GT11 or its
phosphate are involved in the effect of high concentrations of
GT11. The study of the activities of the GT11 analogs reported
here in cell culture should help clarify themechanism underlying
the effects of high concentrations of GT11 in cultured cells.
Several inhibitors of the neutral/alkaline,13,21,22 and the
acidic ceramidase22,23 have been reported. The latter include
N-oleoylethanolamine, which also affects other amide
hydrolases24 and has a rather low potency, (1R,2R)-2-(N-tetra-
decylamino)-1-(4-nitrophenyl)-1,3-propanediol (AD2646)25
and (1R,2R)-2-(N-tetradecanoylamino)-1-(4-nitrophenyl)-1,3-
propanediol (B-13).22,23 The latter two compounds suppress
acid ceramidase activity with good potencies and the activity
of the neutral/alkaline isoform is affected only slightly. The
mechanism of inhibition by these compounds is unknown.
In this article we report the ﬁrst family of mechanism-based
inhibitors of the acid ceramidase with potencies in the low lM
range in an acidic ceramidase preparation. Remarkably, these
compounds have a good selectivity toward of the neutral
ceramidase in vitro, which requires around 20 fold higher
concentrations for inhibition. Since a-ketoamides 5–7 have dual
inhibitory activity on both dihydroceramide desaturase and
the acidic ceramidase, they should induce an accumulation of
dihydroceramide in cultured cells. Therefore, this family should
prove very useful to evaluate the role of dihydroceramide in cell
biology, a matter of current debate. Whereas the cyclopropene
ring is crucial for dihydroceramide desaturase inhibition,18 it
is not likely essential for inhibition of the acidic ceramidase.
By similarity to other serine or cysteine hydrolases, the later
activity does probably lie in the a-ketoamide unit, by virtue
of which these molecules behave as reversible transition state
mimic inhibitors.14 Thus, we anticipate that a-ketoamides of
sphingoid bases are attractive candidates as leads in the search
for potent and speciﬁc ceramidase inhibitors. Work along this
line is ongoing in our laboratories.
Conclusions
In conclusion, either N-methyl substitution or replacement
of the amide a-carbonyl methylene by oxygen in the di-
hydroceramide desaturase inhibitor GT11 result in inactive
compounds, whereas activity is retained in urea (3), thiourea
(4) and a-ketoamide (5–7) analogs of GT11. This difference can
be explained considering that the inactive compound cannot
comply with hydrogen bonding events required for inhibition.
Furthermore, the a-ketoamides 5–7 have been identiﬁed as the
ﬁrst mechanism-based inhibitors of the acid ceramidase with
potencies in the low lM range. Since a-ketoamides 5–7 have
dual inhibitory activity on both dihydroceramide desaturase and
the acidic ceramidase, they should induce an accumulation of
dihydroceramide in cultured cells. Therefore, these compounds
should prove very useful to decipher the role of dihydroceramide
in cell biology.
Experimental
Synthesis of compounds
(4′R,5′S)-N-[2,2-Dimethyl-4-(2-tridecylcyclopropen-1-yl)-1,3-
dioxan-5-yl]octanamide (8). A solution of GT11 (50 mg,
0.11 mmol), pyridinium p-toluenesulfonate (5.7 mg,
0.023 mmol) and 2,2-dimethoxypropane (0.280 ml, 2.28 mmol)
in CH2Cl2 (5 ml) was stirred at room temperature for 12 h. After
this time, the solvent was removed, the residue was dissolved in
ethyl acetate and the organic solution was sequentially washed
with saturated solution of NaHCO3 and brine. Solvent removal
under reduced pressure afforded a reaction mixture that was
puriﬁed by silica gel column chromatography (CH2Cl2–MeOH
98 : 2) to furnish 36mg (0.075mmol, 66%) of amide 8. 1H-NMR
(300 MHz, CDCl3): 0.87 (t, 6H, J = 6.6 Hz), 1.01 (s, 2H),
1.2–1.4 (m, 28H), 1.58 (m, 4H), 2.17 (t, J = 7.5 Hz, 2H), 2.43
(t, J = 7.5 Hz, 2H), 3.68 (m, 1H), 4.07 (m, 2H), 4.69 (d, J =
6.5 Hz, 1H), 5.84 (d, J = 8.0). 13C-NMR (75 MHz, CDCl3):
8.2, 14.0, 14.1, 22.5, 22.6, 24.1, 25.3, 25.6, 25.9, 27.0, 29.0, 29.1,
29.3, 29.4, 29.5, 29.6, 31.65, 31.8, 36.8, 46.7, 62.0, 69.4, 98.8,
107.1, 116.0, 172.6.
(4′R,5′S)-N-[2,2-Dimethyl-4-(2-tridecylcyclopropen-1-yl)-1,3-
dioxan-5-yl]-N-methyloctanamide (9). A solution of 8 (36 mg,
0.07 mmol) in anhydrous tetrahydrofuran (2 ml) and anhydrous
dimethyl sulfoxide (2 ml) was successively treated under argon
with NaH (3 mg, 0.07 mmol) and CH3I (21.3 mg 0.15 mmol).
The reaction was stirred at room temperature for 12 h and the
product was extracted with diethyl ether. The organic layer was
washed with brine and the solvent was removed under reduced
pressure to afford a reaction mixture (22 mg, 0.045 mmol, 64%)
that was used in the following reaction without puriﬁcation.
1H-NMR (300 MHz, CDCl3): 0.87 (t, J = 6.9 Hz, 6H), 1.01
(m, 1H), 1.2–1.4 (m, 28 H), 1.42 (d, J = 11.1 Hz, 3H), 1.55
(d, J = 7.8 Hz, 3H), 1.58 (m, 4H), 2.27 (m, 2H), 2.40 (t, 2H),
3.90 (s, 1.5H), 3.05 (s, 1.5H), 3.91 (m, 2H), 4.17 (m, 1H), 5.02
(d, J = 9 Hz, 1H), 5.84 (d, J = 6.6 Hz). 13C-NMR (75 MHz,
CDCl3): 7.6, 7.8, 14.1, 19.9, 22.6, 22.67, 25.2, 26.0, 27.1. 27.18,
27.6, 28.1, 28.5, 29.1, 29.3, 29.6, 31.7, 31.9, 33.2, 34.3, 37.0,
54.5, 59.8, 61.1, 65.0, 66.2, 99.1, 99.2, 105.6, 106.5, 116.1, 117.2,
173.2, 173.4.
(1′S,2′R)-N -[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
prop-en-1-yl)ethyl]-N-methyloctanamide (1). Crude amide 9
(20 mg, 0.040 mmol) and p-toluenesulfonic acid (3.25 mg,
0.02 mmol) were dissolved inMeOH (2ml) and the solution was
stirred at room temperature for 2 h. After this time, the solvent
was evaporated and the residue was dissolved in ethyl acetate.
The organic solution was successively washed with saturated
solution of NaHCO3 and brine. The solvent was removed under
reduced pressure to afford a reaction mixture that was puriﬁed
by silica gel column chromatography (CH2Cl2–MeOH 98 : 2)
to furnish 17 mg (0.038 mmol, 95%) of 1 (oil). [a]D: +1.03 (c
0.68, CHCl3, 20 ◦C). 1H-NMR (300 MHz, CDCl3): 0.87 (t, J =
6.3 Hz, 6H), 0.96 (AB system, J = 8.4 Hz, 2H), 1.01 (AB system,
J = 8.4 Hz, 2H), 1.2–1.4 (m, 28H), 1.58 (m, 4H), 2.30 (t, J =
7.5 Hz 2H), 2.43 (dt, J = 7.2 and 1.2 Hz, 2H), 2.85 (s, 0.60H),
3.01 (s, 2.40H), 3.99 (m, 3H), 4.86 (d, J = 7.5 Hz, 0.60H), 5.06
(d, J = 5.7 Hz, 2.40H). 13C-NMR (75 MHz, CDCl3): 8.0, 14.1,
22.6, 22.67, 24.9, 25.8, 27.2, 29.1, 29.3, 29.4, 29.47, 29.6, 31.6,
3 7 1 0 O r g . B i o m o l . C h e m . , 2 0 0 5 , 3 , 3 7 0 7 – 3 7 1 2
D
ow
nl
oa
de
d 
on
 1
7 
N
ov
em
be
r 2
01
0
Pu
bl
ish
ed
 o
n 
08
 S
ep
te
m
be
r 2
00
5 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/B
510
198
K
View Online
31.9, 34.4, 36.3, 61.6, 64.1, 67.8, 108.2, 114.2, 175.2. IR (ﬁlm):
3397, 2926, 1623, 1463, 1034. ESI-MS: m/z 452 [M + 1]+, 474
[M + Na]+. HR-MS calcd for C28H53NO3: 451.40254; found:
451.40258.
(1′S,2′R)-Octyl 2-hydroxy-1-hydroxymethyl-2-(2-tridecylcyl-
cyclopropen-1-yl)ethyl]carbamate (2). Triethylamine (11.40 ll,
0.081mmol) and octyl chloroformate (10.57 ll, 0.054mmol) was
added at 0 ◦C to aminodiol 10 (17 mg, 0.054 mmol) dissolved in
anhydrous CH2Cl2 (3 ml). The mixture was stirred overnight at
room temperature and the product was extracted with CH2Cl2.
The organic layer was sequentially washed with 1 M HCl,
saturated solution ofNaHCO3 and brine. Solvent removal under
vacuum afforded a reaction mixture that was puriﬁed by silica
gel column chromatography (hexane–ethyl acetate 1 : 1) to give
10 mg (0.022 mmol, 41%) of 2. Mp: 47 ◦C. [a]D: +1.75 (c 0.57,
CHCl3, 20 ◦C). 1H-NMR(300MHz,CDCl3): 0.87 (t, J = 6.9Hz,
6H), 1.01 (s, 2H), 1.2–1.4 (m, 32 H), 1.59 (m, 4H), 2.46 (dt,
J = 7.5 and 1.5 Hz, 2H), 3.76 (m, 1H), 3.87 (m, 1H), 4.06 (t,
J = 6.9 Hz, 2H), 4.86 (s, 1H), 5.51 (d, J = 8.4 Hz). 13C-NMR
(75 MHz, CDCl3): 8.2, 14.1, 22.6, 22.6, 25.8, 27.2, 28.9, 29.1,
29, 2, 29.3, 29.4, 29.5, 29.6, 31.7, 31.9, 54.7, 63.2, 65.4, 70.7,
107.5, 115.4, 156.9. IR (ﬁlm): 3379, 2925, 1700, 1463, 1043. [a]D:
+1.87 (c 0 88, CHCl3, 20 ◦C). ESI-MS: m/z 450 [M + 1]+, 490
[M + Na]+. HR-MS calcd for C28H53NO4: 467.39746; found:
467.39749.
(1′S,2′R)-1-[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)ethyl]-3-octylurea (3). A solution of aminodiol 10
(7 mg, 0.02 mmol) in CH3CN (2.4 ml) and diethyl ether (1.4 ml)
was reacted with octyl isocyanate (3.5 ll, 0.02 mmol) at room
temperature for 12 h. After this time, the solvent was removed
under vacuum and the resulting residue was puriﬁed by silica
gel column chromatography (CH2Cl2–MeOH 97 : 3) to furnish
7 mg (0.015 mmol, 75%) of the expected urea 3 (oil). 1H-NMR
(300 MHz, CDCl3): 0.87 (t, J = 6.9 Hz, 6H), 1.00 (s, 2H),
1.2–1.4 (m, 28H), 1.52 (m, 4H), 2.45 (dt, J = 7.2 and 1.2 Hz,
2H), 3.14 (q, J = 6.9 and 2.6 Hz, 2H), 3.72 (dd, J = 3.3 and
11.1 Hz, 1H), 3.82 (dd, J = 4.5 Hz and 11.1 Hz, 1H), 4.04 (m,
3H), 4.62 (t, J = 4.5 Hz, 2H), 4.84 (s, 1H), 5.25 (d, J = 7.5 Hz).
13C-NMR (75 MHz, CDCl3): 8.3, 14.2, 22.8, 25.6, 26.9, 27.9,
29.2, 29.28, 29.5, 29.6, 30.0, 31.7, 31.9, 40.7, 54.8, 63.7, 70.8,
107.6, 115.2, 158.5. IR (ﬁlm): 3335, 2924, 1628, 1463, 1021.
ESI-MS: m/z 467 [M + 1]+, 489 [M + Na]+. HR-MS calcd for
C28H54N2O3: 466.41344; found: 466.41339.
(1′S, 2′R)-1-[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)octyl]-3-hexylthiourea (4). Octyl isothiocyanate
20 ll (0.12 mmol) was added to a solution of aminodiol 10
(37.3 mg, 0.12 mmol) in CH3CN (2.4 ml) and diethyl ether
(1.4 ml). After 72 h of stirring at 25 ◦C, the solvent was removed
under reduced pressure and the resulting residue was puriﬁed by
silica gel column chromatography. Elution with CH2Cl2–MeOH
(97 : 3) gave 30 mg (0.066 mmol, 55%) of thiourea 4 (oil). 1H-
NMR (300 MHz, CDCl3): 0.87 (t, J = 7 Hz, 6H), 1.04 (s, 2H),
1.2–1.4 (m, 28 H), 1.59 (m, 4H), 2.47 (dt, 2H, J = 7.5 and 1.5),
3.34 (bs, 2H), 3.85 (dd, J = 11.5 and 3.5 Hz), 3.94 (dd, J = 11
and 3 Hz, 1H), 4.6 (bs, 1H), 5.04 (s, 1H), 6.23 (d, J = 7.5 Hz,
1H), 6.57 (bs, 1H). 13C-NMR (75 MHz, CDCl3): 8.4, 13.9, 14.2,
22.5, 22.7, 25.9, 26.6, 27.3, 28.7, 29.3, 29.4, 29.46, 29.6, 29.66,
31.4, 31.9, 57.8, 63.3, 70.9, 107.3, 115.9, 181.4. IR (ﬁlm): 3283,
2930, 1551, 1527, 1461, 1024. ESI-MS: m/z 455 [M + 1]+, 477
[M + Na]+. HR-MS calcd for C28H54N2O2S: 482.39060; found:
482.39057
a-ketoamides. To a solution of aminodiol 10 (0.1 mmol),
EDC (0.15 mmol) and HOBT (0.15 mmol) was added the a-
ketoacid (0.15 mmol) dissolved in CH2Cl2 (2 mL). The reaction
mixture was stirred at 25 ◦C for 12 h, CH2Cl2 (10 mL) was
added and the organic phase was washed with brine and dried
(MgSO4). The solvent was removed under vacuum and the
resulting residue was puriﬁed by column chromatography on
silica gel eluting with a mixture of CH2Cl2–MeOH 97 : 3.
Compound were obtained as colorless oils.
(1′S,2′R)-N -[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)ethyl]-2-oxobutanamide (5). Yield 55% from
0.096 mmol of 10 and 2-oxobutanoic acid (0.11 mmol). [a]D
−5.21 (c 0.69, CHCl3, 20 ◦C). 1H-NMR (300 MHz, CDCl3):
0.87 (t, J = 6.6 Hz, 3H), 1.03 (s, 2H), 1.12 (t, J = 6.9 Hz, 3H),
1.2–1.4 (m, 20H), 1.56 (t, J = 7.2 Hz, 2H), 2.46 (dt, J = 1.5 and
7.5 Hz, 2H), 2.95 (q, J = 12.0 and 4.8 Hz, 2H), 3.77 (dd, J =
11.7 and 3.3 Hz, 1H), 3.96 (dd, J = 11.5 and 4.0 Hz, 1H), 4.14
(m, 1H), 4.87 (d, J = 3.9 Hz, 1H), 7.71 (d, J = 7.5 Hz, 1H).
IR (ﬁlm): 3365, 2933, 1658, 1462, 1022. 13C-NMR (75 MHz,
CDCl3): 7.1, 8.3, 14.2, 22.7, 25.8, 27.3, 29.3, 29.4, 29.5, 29.65,
29.68, 30.3, 31.9, 53.6 62.6, 70.1, 107.2, 116.1 160.3, 199.1.
ESI-MS: m/z 396 [M + 1]+, 418 [M + Na]+. HR-MS calcd for
C23H41NO4: 395.30356; found: 395.30351.
(1′S,2′R)-N -[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)ethyl]-2-oxooctanamide (6). Yield 71% from
0.266 mmol of 10 and 2-oxooctanoic acid (0.30 mmol). [a]D
+5.08 (c 0.45, CHCl3, 20 ◦C). 1H-NMR (300 MHz, CDCl3):
0.87 (t, J = 6.9 Hz, 6H), 1.01 (s, 2H), 1.2–1.4 (m, 30H), 1.58
(m, 4H), 2.45 (dt, J ′ = 7.5 and 1.5 Hz, 2H), 2.90 (t, J = 7.5 Hz,
2H), 3.77 (dd, J = 11.7 and 3.9 Hz, 1H), 3.91 (dd, J = 11.4 and
3.9 Hz, 1H), 4.12 (m, 1H), 4.87 (d, 3.9 Hz, 1H), 7.70 (d, J =
8.4 Hz, 1H). 13C-NMR (75 MHz, CDCl3): 8.3, 13.9, 14.1,.22.4,
22.6, 23.1, 25.8, 27.2, 28.7, 29.34, 29.36, 29.4, 29.5, 29.64,
29.67, 31.5, 31.9, 36.8, 53.8 62.5, 69.8, 107.2, 116.0, 160.4,
199.7. IR (ﬁlm): 3365, 2926, 1672, 1530, 1461. ESI-MS m/z
474 [M + Na]+, 925 [2M + Na]+. HR-MS calcd for C27H49NO4:
451.36616; found: 451.36610
(1′S,2′R)-N -[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)ethyl]-2-oxobenzamide (7). Yield 57% from
0.266 mmol of 10 and 2-oxobenzoic acid (0.30 mmol). [a]D
+4.97 (c 0.36, CHCl3, 20 ◦C). 1H-NMR (300 MHz, CDCl3):
0.87 (t, J = 6.9 Hz, 3H), 1.04 (s, 2H), 1.2–1.4 (m, 20 H), 1.56 (t,
J = 7.2 Hz, 2H), 2.46 (dt, J = 7.5 and 1.5 Hz, 2H), 3.86 (dd, J =
11.4 and 3.6 Hz, 1H), 4.01 (dd, J = 11.7 and 3.9 Hz, 1H), 4.28
(m, 1H), 4.95 (d, J = 3.9 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.62
(tt, J = 7.5 and 1.5 Hz, 1H), 7.86 (d, J = 7.5 Hz, 1H), 8.07 (d,
J = 6.9 Hz, 0.5H, Har), 8.29 (dd, J = 7.8 Hz, 1.5H). 13C-NMR
(75 MHz, CDCl3): 8.2, 14.0, 22.5, 25.7, 27.1, 29.2, 29.3, 29.4,
29.56, 29.58, 31.8, 53.7, 62.5, 69.8, 107.1, 116.0, 128.3, 128.4,
130.0, 131.0, 133.0, 134.4, 162.6, 187.4. IR (ﬁlm): 3315, 2924,
1665, 1460, 1267, 1042. ESI-MS m/z 466 [M + Na]+, 909
[2M + Na]+. HR-MS calcd for C27H41NO4: 443.30356; found:
443.30359.
(1′S,2′R)-N -[2-Hydroxy-1-hydroxymethyl-2-(2-tridecylcyclo-
propen-1-yl)ethyl]-12-[(5-nitro-2,1,3-benzoxazol-6-yl)amino]-
dodecanamide (GT11-C12NBD). The same procedure
described for a-ketoamides was applied to 0.048 mmol of
10 and 12-(5-nitro-2,1,3-benzoxazol-6-yl)aminododecanoic
acid (0.050 mmol) to prepare GT11-C12NBD in 81% yield.
1H-NMR (300 MHz, CDCl3): 0.87 (t, J = 7.0 Hz, 3H), 1.01 (s,
2H), 1.20–1.40 (s, 34H), 1.56 (m, 2H), 1.60–1.82 (m, 4H), 2.25
(t, J = 7.5 Hz, 2H), 2.44 (dt, J = 7.5 and 1.5 Hz, 2H), 3.31 (m,
2H), 3.49 (q, J = 6.0 Hz, 2H), 3.74 (dd, J = 11.5 and 3.5 Hz,
1H), 3.83 (s, 1H), 3.90 (dd, J = 11.5 Hz and 3.5 Hz, 1H), 4.17
(m, 1H), 4.85 (s, 1H), 6.17 (d, J = 8.5 Hz, 1H), 6.42 (d, J =
7.0 Hz, 1H), 6.80 (bs, 1H), 8.50 (d, J = 8.5 Hz, 1H). 13C-NMR
75 MHz, CDCl3): 8.1, 14.1, 22.6, 24.6, 25.8, 26.1, 27.2, 27.8,
29.3, 29.3, 29.4, 29.6, 31.9, 36.0, 43.6, 53.3, 63.0, 70.6, 96.6,
98.5, 107.3, 115.7, 123.6, 136.5, 143.9, 144.2, 173.2. IR (ﬁlm):
2923, 2852, 1633, 1556, 1504, 1297, 800. ESI-MS:m/z 673 [M+
1]+, 696 [M + Na]+. HR-MS calcd for C37H61N5O6: 671.46218;
found: 671.46208.
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Enzyme activities
Dihydroceramide desaturase. The effect of compounds on
this enzyme was determined as reported in previous articles.12,17
Ceramidase. Fresh rat livers (50–60 g) were homogenized
in 150 ml of 20 mM cold phosphate buffer (pH 7.4) containing
0.25Msucrose, 1mMEDTA, and 0.2mMphenylmethylsulfonyl
ﬂuoride. The homogenate was centrifuged at 1000g for 10 min,
and the pellet was washed twice with 50 ml of the same
buffer. After centrifugation (1000g for 10 min), the combined
supernatants were centrifuged at 10 000g for 30 min. The
pellet of this centrifugation was resuspended and stirred for
1 h in 145 ml of 20 mM Tris-HCl, pH 7.4, 1 mM EDTA,
0.2 mM phenylmethylsulfonyl ﬂuoride, 0.5% Triton X-100. The
supernatant obtained after centrifugation of the mixture at
10 000g for 30 min was used as a source of neutral ceramidase.20
Todetermine the activity of the acid ceramidase, rat livers (50–
60 g) were homogenized in 150ml of cold 50mM sodium acetate
buffer (pH4.5) containing 0.25Msucrose and 1mMEDTA.The
homogenate was centrifuged at 10 000g for 10 min at 4 ◦C and
the supernatant was used as a source of acid ceramidase.
The activities of both enzymes were determined following a
modiﬁcation of reported procedures.19 Different amounts of the
test compound and 3 nmol of Cer-C12NBD were dissolved in
ethanol (2 ll) and the ﬁnal volume was brought to 75 ll with
the suitable buffer (neutral ceramidase, 25 mM tris-HCl, pH 7.4;
acid ceramidase, 25 mM sodium acetate, pH 4.5, 0.25% Triton
X-100). To this solution, 300–480 lg of protein was added and
the suspension was incubated at 37 ◦C for either 1 hour (neutral)
or 3 hours (acidic). The reactions were stopped by addition
of either methanol (0.4 ml, neutral ceramidase) or 0.25 vol of
100 mM glycine buffer pH 10 and then methanol (0.4 ml, acid
ceramidase) and the reaction mixtures were vigorously stirred
and centrifuged at 5000g for 2 min. The supernatants were
loaded onto a Macro Prep High Q, (Bio-Rad) column, which
was washed sequentially with 1 ml of 25 mM tris-HCl, pH 7.5,
and 1 ml of methanol–tris-HCl buffer (1 : 1) to recover the
starting substrate. The enzymatically borne 12-(4-nitrobenzo-2-
oxa-1,3-diazolo)dodecanoic acid was eluted with acetic acid–
methanol (1 : 1) (1 ml). The ﬂuorescence of 200 ll aliquots
of each acid-eluted fraction was measured in a 96-well plate
reader at excitation and emission wavelengths of 460 of 540 nm,
respectively. Actual amounts of acid were calculated from a
standard curve prepared by serial dilutions in the elution solvent
mixture of a 30 lM solution of synthetic 12-(4-nitrobenzo-2-
oxa-1,3-diazolo)dodecanoic acid.
Kinetic parameters of hydrolysis of Cer-C12NBD and GT11-
C12NBD by rat liver ceramidases. Enzyme activities were
determined as described above with 300 lg (neutral) or 480 lg
(acidic) of protein. Different concentrations of the ﬂuorescent
derivatives from 10 to 160 lMwere incubated with the appropri-
ate enzyme preparation for 1 h (neutral) or 3 h (acidic) and the
amounts of released acid were determined after ion exchange
chromatography. The data were obtained from a representative
experiment with three replicates.
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